FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1992-2001 May 12, 2005 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Advances in the care of patients with cystic fibrosis have improved survival, and as a result, patients with the disease now often live beyond the third decade.¹ In addition, developments in the understanding of the genetics and molecular mechanisms of cystic fibrosis have led to new targets for treatment and an increasingly hopeful outlook. This review summarizes the mechanisms underlying the disease, the sequelae stemming from the absence of a functioning cystic fibrosis transmembrane conductance regulator (CFTR), and the therapeutic strategies devised to correct these abnormalities. Progress in the supportive care of patients with the disease has been reviewed elsewhere.^2,3,4

Historical Background

. . . [Full Text of this Article]

Structure and Function of CFTR

Pathobiologic Features of Organ System Disease

Mechanism Underlying the Sweat-Gland Abnormality

Bioelectric Measurements in the Lung

Glandular Secretion and Small-Airway Physiology

Mutations in CFTR And Their Consequences

Interventions Tailored to Specific CFTR Defects

Summary

Source Information

From the Gregory Fleming James Cystic Fibrosis Research Center (S.M.R., S.M., E.J.S.), and the Departments of Medicine (S.M.R., E.J.S.), Pediatrics (S.M.R.), Genetics (E.J.S.), and Physiology and Biophysics (E.J.S.), University of Alabama at Birmingham, Birmingham.

Dr. Rowe and Ms. Miller contributed equally to this article.

Address reprint requests to Dr. Sorscher at the Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, 1530 3rd Ave. S., MCLM 796, Birmingham, AL 35294, or at sorscher@uab.edu.

This article has been cited by other articles:

• Loo, T. W., Bartlett, M. C., Clarke, D. M. (2008). Arginines in the First Transmembrane Segment Promote Maturation of a P-glycoprotein Processing Mutant by Hydrogen Bond Interactions with Tyrosines in Transmembrane Segment 11. J. Biol. Chem. 283: 24860-24870 [Abstract] [Full Text]  
• Haggie, P. M., Verkman, A. S. (2008). Monomeric CFTR in Plasma Membranes in Live Cells Revealed by Single Molecule Fluorescence Imaging. J. Biol. Chem. 283: 23510-23513 [Abstract] [Full Text]  
• Gooderham, W. J., Bains, M., McPhee, J. B., Wiegand, I., Hancock, R. E. W. (2008). Induction by Cationic Antimicrobial Peptides and Involvement in Intrinsic Polymyxin and Antimicrobial Peptide Resistance, Biofilm Formation, and Swarming Motility of PsrA in Pseudomonas aeruginosa. J. Bacteriol. 190: 5624-5634 [Abstract] [Full Text]  
• Freudenberg, F., Broderick, A. L., Yu, B. B., Leonard, M. R., Glickman, J. N., Carey, M. C. (2008). Pathophysiological basis of liver disease in cystic fibrosis employing a {Delta}F508 mouse model. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G1411-G1420 [Abstract] [Full Text]  
• Kremer, T. M., Zwerdling, R. G., Michelson, P. H., O'Sullivan, B. P. (2008). Intensive Care Management of the Patient With Cystic Fibrosis. J Intensive Care Med 23: 159-177 [Abstract]  
• Gaggar, A., Jackson, P. L., Noerager, B. D., O'Reilly, P. J., McQuaid, D. B., Rowe, S. M., Clancy, J. P., Blalock, J. E. (2008). A Novel Proteolytic Cascade Generates an Extracellular Matrix-Derived Chemoattractant in Chronic Neutrophilic Inflammation. J. Immunol. 180: 5662-5669 [Abstract] [Full Text]  
• Hirsh, A. J., Zhang, J., Zamurs, A., Fleegle, J., Thelin, W. R., Caldwell, R. A., Sabater, J. R., Abraham, W. M., Donowitz, M., Cha, B., Johnson, K. B., St. George, J. A., Johnson, M. R., Boucher, R. C. (2008). Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease. J. Pharmacol. Exp. Ther. 325: 77-88 [Abstract] [Full Text]  
• Lubamba, B., Lecourt, H., Lebacq, J., Lebecque, P., De Jonge, H., Wallemacq, P., Leal, T. (2008). Preclinical Evidence that Sildenafil and Vardenafil Activate Chloride Transport in Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 177: 506-515 [Abstract] [Full Text]  
• Vij, N., Amoako, M. O., Mazur, S., Zeitlin, P. L. (2008). CHOP Transcription Factor Mediates IL-8 Signaling in Cystic Fibrosis Bronchial Epithelial Cells. Am. J. Respir. Cell Mol. Bio. 38: 176-184 [Abstract] [Full Text]  
• Berdiev, B. K., Cormet-Boyaka, E., Tousson, A., Qadri, Y. J., Oosterveld-Hut, H. M. J., Hong, J. S., Gonzales, P. A., Fuller, C. M., Sorscher, E. J., Lukacs, G. L., Benos, D. J. (2007). Molecular Proximity of Cystic Fibrosis Transmembrane Conductance Regulator and Epithelial Sodium Channel Assessed by Fluorescence Resonance Energy Transfer. J. Biol. Chem. 282: 36481-36488 [Abstract] [Full Text]  
• Haggie, P. M., Verkman, A. S. (2007). Cystic Fibrosis Transmembrane Conductance Regulator-independent Phagosomal Acidification in Macrophages. J. Biol. Chem. 282: 31422-31428 [Abstract] [Full Text]  
• Rowe, S. M., Varga, K., Rab, A., Bebok, Z., Byram, K., Li, Y., Sorscher, E. J., Clancy, J. P. (2007). Restoration of W1282X CFTR Activity by Enhanced Expression. Am. J. Respir. Cell Mol. Bio. 37: 347-356 [Abstract] [Full Text]  
• Poschet, J. F., Timmins, G. S., Taylor-Cousar, J. L., Ornatowski, W., Fazio, J., Perkett, E., Wilson, K. R., Yu, H. D., de Jonge, H. R., Deretic, V. (2007). Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L712-L719 [Abstract] [Full Text]  
• Mayer-Hamblett, N., Ramsey, B. W., Kronmal, R. A. (2007). Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis. Proc Am Thorac Soc 4: 370-377 [Abstract] [Full Text]  
• Gaggar, A., Li, Y., Weathington, N., Winkler, M., Kong, M., Jackson, P., Blalock, J. E., Clancy, J. P. (2007). Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L96-L104 [Abstract] [Full Text]  
• Xu, W. M., Shi, Q. X., Chen, W. Y., Zhou, C. X., Ni, Y., Rowlands, D. K., Yi Liu, G., Zhu, H., Ma, Z. G., Wang, X. F., Chen, Z. H., Zhou, S. C., Dong, H. S., Zhang, X. H., Chung, Y. W., Yuan, Y. Y., Yang, W. X., Chan, H. C. (2007). Cystic fibrosis transmembrane conductance regulator is vital to sperm fertilizing capacity and male fertility. Proc. Natl. Acad. Sci. USA 104: 9816-9821 [Abstract] [Full Text]  
• Wang, Z., Wang, J., Tantoso, E., Wang, B., Tai, A. Y.P., Ooi, L. L.P.J., Chong, S. S., Lee, C. G.L. (2007). Signatures of recent positive selection at the ATP-binding cassette drug transporter superfamily gene loci. Hum Mol Genet 16: 1367-1380 [Abstract] [Full Text]  
• Preumont, V., Hermans, M. P., Lebecque, P., Buysschaert, M. (2007). Glucose Homeostasis and Genotype-Phenotype Interplay in Cystic Fibrosis Patients With CFTR Gene {Delta}F508 Mutation. Diabetes Care 30: 1187-1192 [Abstract] [Full Text]  
• Sidani, S. M., Kirchhoff, P., Socrates, T., Stelter, L., Ferreira, E., Caputo, C., Roberts, K. E., Bell, R. L., Egan, M. E., Geibel, J. P. (2007). {Delta}F508 Mutation Results in Impaired Gastric Acid Secretion. J. Biol. Chem. 282: 6068-6074 [Abstract] [Full Text]  
• Battezzati, A, Battezzati, P M, Costantini, D, Seia, M, Zazzeron, L, Russo, M C, Dacco, V, Bertoli, S, Crosignani, A, Colombo, C (2007). Spontaneous hypoglycemia in patients with cystic fibrosis. Eur J Endocrinol 156: 369-376 [Abstract] [Full Text]  
• Jouret, F., Bernard, A., Hermans, C., Dom, G., Terryn, S., Leal, T., Lebecque, P., Cassiman, J.-J., Scholte, B. J., de Jonge, H. R., Courtoy, P. J., Devuyst, O. (2007). Cystic Fibrosis Is Associated with a Defect in Apical Receptor-Mediated Endocytosis in Mouse and Human Kidney. J. Am. Soc. Nephrol. 18: 707-718 [Abstract] [Full Text]  
• Burgel, P.-R., Montani, D., Danel, C., Dusser, D. J, Nadel, J. A (2007). A morphometric study of mucins and small airway plugging in cystic fibrosis. Thorax 62: 153-161 [Abstract] [Full Text]  
• Moskwa, P., Lorentzen, D., Excoffon, K. J. D. A., Zabner, J., McCray, P. B. Jr., Nauseef, W. M., Dupuy, C., Banfi, B. (2007). A Novel Host Defense System of Airways Is Defective in Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 175: 174-183 [Abstract] [Full Text]  
• Livraghi, A., Randell, S. H. (2007). Cystic Fibrosis and Other Respiratory Diseases of Impaired Mucus Clearance. Toxicol Pathol 35: 116-129 [Abstract] [Full Text]  
• Herlitz, G. N., Sternberg, D. I., Palazzo, R., Arcasoy, S., Sonett, J. R. (2006). Treatment of Bronchomalacia in Cystic Fibrosis by Silicone Stent. Ann. Thorac. Surg. 82: 2268-2270 [Abstract] [Full Text]  
• Pan, J., Luk, C., Kent, G., Cutz, E., Yeger, H. (2006). Pulmonary Neuroendocrine Cells, Airway Innervation, and Smooth Muscle Are Altered in Cftr Null Mice. Am. J. Respir. Cell Mol. Bio. 35: 320-326 [Abstract] [Full Text]  
• O'Sullivan, B. P., Zwerdling, R. G., Dorkin, H. L., Comeau, A. M., Parad, R. (2006). Early Pulmonary Manifestation of Cystic Fibrosis in Children With the {Delta}F508/R117H-7T Genotype. Pediatrics 118: 1260-1265 [Abstract] [Full Text]  
• Vij, N., Fang, S., Zeitlin, P. L. (2006). Selective Inhibition of Endoplasmic Reticulum-associated Degradation Rescues {Delta}F508-Cystic Fibrosis Transmembrane Regulator and Suppresses Interleukin-8 Levels: THERAPEUTIC IMPLICATIONS. J. Biol. Chem. 281: 17369-17378 [Abstract] [Full Text]  
• Delgado, M. A., Poschet, J. F., Deretic, V. (2006). Nonclassical Pathway of Pseudomonas aeruginosa DNA-Induced Interleukin-8 Secretion in Cystic Fibrosis Airway Epithelial Cells.. Infect. Immun. 74: 2975-2984 [Abstract] [Full Text]  
• Li, Y., Wang, W., Parker, W., Clancy, J. P. (2006). Adenosine Regulation of Cystic Fibrosis Transmembrane Conductance Regulator through Prostenoids in Airway Epithelia. Am. J. Respir. Cell Mol. Bio. 34: 600-608 [Abstract] [Full Text]  
• Anderson, C. L., Delisle, B. P., Anson, B. D., Kilby, J. A., Will, M. L., Tester, D. J., Gong, Q., Zhou, Z., Ackerman, M. J., January, C. T. (2006). Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism. Circulation 113: 365-373 [Abstract] [Full Text]  
• Kulka, M., Dery, R., Nahirney, D., Duszyk, M., Befus, A. D. (2005). Differential Regulation of Cystic Fibrosis Transmembrane Conductance Regulator by Interferon {gamma} in Mast Cells and Epithelial Cells. J. Pharmacol. Exp. Ther. 315: 563-570 [Abstract] [Full Text]  
• Lee, R. L., Rancourt, R. C., del Val, G., Pack, K., Pardee, C., Accurso, F. J., White, C. W. (2005). Thioredoxin and dihydrolipoic acid inhibit elastase activity in cystic fibrosis sputum. Am. J. Physiol. Lung Cell. Mol. Physiol. 289: L875-L882 [Abstract] [Full Text]